Cannabidiol, or CBD, is a hemp extract that’s been slowly gaining traction in the medical, sports, and health and wellness communities. It is one of the over 100 cannabinoids produced by hemp, and it stands out from the rest in a mighty way. According to its users, the chemical is a potent natural medicine, capable of acting against a host of conditions from chronic pain to high blood pressure and anxiety.
However, despite these claims, there’s little scientific evidence to back them up. The only approved CBD drug is epidiolex, and it’s used to manage seizures in two rare and hard to treat…
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.